Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 21;12(5):e005095. doi: 10.1161/CIRCOUTCOMES.118.005095

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors.

Circulation: Cardiovascular Quality and Outcomes is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

PMC Copyright notice

Figure 2. — Observed vs predicted mortality in SERAPHIN. Observed mortality for patients receiving (A) placebo or (B) macitentan 10 mg in SERAPHIN compared with predicted mortality for the overall SERAPHIN patient population had they received real-world treatment. n=742 for the predicted curve (the number of patients at risk at each timepoint are not available for the predicted curves as the Kaplan-Meier estimates are based on probability predictions). SERAPHIN indicates Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome.